[1] 刘洁,付靓,史志涛,等.腹腔镜术在结直肠癌伴肝转移中的安全性和有效性评价[J].现代医学,2018,46(8):843-847.
[2] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)结直肠癌诊疗指南(2019.V1)[M].北京:人民卫生出版社,2019:1-139.
[3] BI F,WANG Q,DONG Q,et al.Circulating tumor DNA in colorectal cancer:opportunities and challenges[J].Am J Transl Res,2020,12(3):1044-1055.
[4] FAN H C,BLUMENFELD Y J,CHITKARA U,et al.Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing[J].Clin Chem,2010,56(8):1279-1286.
[5] CHENG F,SU L,QIAN C.Circulating tumor DNA:a promising biomarker in the liquid biopsy of cancer[J].Oncotarget,2016,7(30):48832-48841.
[6] MOATI E,TALY V,DIDELOT A,et al.Role of circulating tumor DNA in the management of patients with colorectal cancer[J].Clin Res Hepatol Gastroenterol,2018,42(5):396-402.
[7] YOUNG G P,PEDERSEN S K,MANSFIELD S,et al.A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer[J].Cancer Med,2016,5(10):2763-2772.
[8] SONG L,JIA J,PENG X,et al.The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests:A meta-analysis[J].Sci Rep,2017,7(1):3032.
[9] 张钊,刘胜利.KRAS基因突变与结直肠癌研究进展[J].东南大学学报(医学版),2016,35(1):154-157.
[10] THIERRY A R,MOULIERE F,EL MESSAOUDI S,et al.Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA[J].Nat Med,2014,20(4):430-435.
[11] BACHET J B,BOUCHE O,TAEB J,et al.RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC):RASANC,an AGEO prospective multicenter study[J].2017,35(15suppl):11509.
[12] NGUYEN H T,TRAN D H,NGO Q D,et al.Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel Sequencing for Detecting and Quantifying Circulation Tumor DNA in Colorectal Cancer Patients[J].Cancer Invest,2020,38(2):85-93.
[13] BIDARD F C,KIAVUE N,YCHOU M,et al.Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer:A Prospective Ancillary Study to the Unicancer Prodige-14 Trial[J].Cells,2019,8(6):516.
[14] XIE W,XIE L,SONG X.The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer:A meta-analysis[J].Cancer Med,2019,8(3):1218-1231.
[15] CONNOR A A,MCNAMARA K,AL-SUKHNI E,et al.Central,But Not Peripheral,Circulating Tumor Cells are Prognostic in Patients Undergoing Resection of Colorectal Cancer Liver Metastases[J].Ann Surg Oncol,2016,23(7):2168-2175.
[16] NARAYAN R R,GOLDMAN D A,GONEN M,et al.Peripheral circulating tumor DNA detection predicts poor outcomes after liver resection for metastatic colorectal cancer[J].Ann Surg Oncol,2019,26(6):1824-1832.
[17] KEMENY N E,CHOU J F,CAPANU M,et al.KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases[J].Cancer,2014,120(24):3965-3971.
[18] MARGONIS G A,SASAKI K,KIM Y,et al.Tumor biology rather than surgical technique dictates prognosis in colorectal cancer liver metastases[J].J Gastrointest Surg,2016,20(11):1821-1829.
[19] HE Y,MA X,CHEN K,et al.Perioperative circulating tumor DNA in colorectal liver metastases:concordance with metastatic tissue and predictive value for tumor burden and prognosis[J].Cancer Manag Res,2020,12:1621-1630.
[20] BHANGU J S,BEER A,MITTLBOCK M,et al.Circulating free methylated tumor DNA markers for sensitive assessment of tumor burden and early response monitoring in patients receiving systemic chemotherapy for colorectal cancer liver metastasis[J].Ann Surg,2018,268(5):894-902.
[21] LANG H,BAUMGART J,HEINRICH S,et al.Extended molecular profiling improves stratification and prediction of survival after resection of colorectal liver metastases[J].Ann Surg,2019,270(5):799-805.
[22] REINERT T,SCHOLER L V,THOMSEN R,et al.Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery[J].Gut,2016,65(4):625-634.
[23] NORCIC G,JELENC F,CERKOVNIK P,et al.Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection[J].Oncol Lett,2016,12(5):3356-3362.
[24] TARAZONA N,GIMENO-VALIENTE F,GAMBARDELLA V,et al.Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer[J].Annals of Oncology,2019,30(11):1804-1812.
[25] REINERT T,HENRIKSEN T V,CHRISTENSEN E,et al.Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages Ⅰ to Ⅲ colorectal cancer[J].JAMA Oncol,2019,5(8):1124-1131.
[26] BENESOVA L,HALKOVA T,PTACKOVA R,et al.Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA[J].World J Gastroenterol,2019,25(48):6939-6948.
[27] MURRAY D H,SYMONDS E L,YOUNG G P,et al.Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival[J].J Cancer Res Clin Oncol,2018,144(9):1741-1750.
[28] WANG Y,LI L,COHEN J D,et al.Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer[J].JAMA Oncol,2019,5(8):1118-1123.
[29] TIE J,WANG Y,TOMASETTI C,et al.Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage Ⅱ colon cancer[J].Sci Transl Med,2016,8(346):346ra92.
[30] TIE J,COHEN J D,WANG Y,et al.Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage Ⅲ colon cancer[J].JAMA Oncol,2019,5(12):1710-1717.
[31] SCHOLER L V, REINERT T,ORNTOFT M W,et al.Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer[J].Clin Cancer Res,2017,23(18):5437-5445.
[32] SPINDLER K L,PALLISGAARD N,ANDERSEN R F,et al.Changes in mutational status during third-line treatment for metastatic colorectal cancer——results of consecutive measurement of cell free DNA,KRAS and BRAF in the plasma[J].Int J Cancer,2014,135(9):2215-2222.
[33] RUSSO M,SIRAVEGNA G,BLASZKOWSKY L S,et al.Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer[J].Cancer Discov,2016,6(2):147-153.
[34] MAURI G,PIZZUTILO E G,AMATU A,et al.Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer:Systematic review of different strategies[J].Cancer Treat Rev,2019,73:41-53.
[35] CREMOLINI C,ROSSINI D,DELL'AQUILA E,et al.Rechallenge For Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan:A Phase 2 Single-Arm Clinical Trial[J].JAMA Oncol,2019,5(3):343-350.
[36] GARLAN F,LAURENT-PUIG P,SEFRIOUI D,et al.Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL Study)[J].Clin Cancer Res,2017,23(18):5416-5425.
[37] AGOSTINI M,PUCCIARELLI S,ENZO M V,et al.Circulating cell-free DNA:a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy[J].Ann Surg Oncol,2011,18(9):2461-2468.
[38] IWAI T,YAMADA T,TAKAHASHI G,et al.Circulating cell-free long DNA fragments predict post-hepatectomy recurrence of colorectal liver metastases[J].Eur J Surg Oncol,2020,46(1):108-114. |
